Product Description
What is Tirzepatide?
Tirzepatide is a novel medication that is approved by the FDA for the treatment of type 2 diabetes mellitus. Given its potent weight loss properties, buy tirzepatide to be used off-label for obesity treatment.
It works as a dual GLP-1 agonist and GIP agonist to maximize similar benefits that are seen with GLP-1 medications such as semaglutide.It is currently implemented as a second-line diabetes medication, similar to GLP-1 medications, and given as a once-a-week subcutaneous injectable. The FDA approved the peptide Tirzepatide in May 2022.
How Does Tirzepatide Work?
Tirzepatide is a synthetic peptide; and a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. It is composed of 39 amino acids and is an analog of the gastric inhibitory polypeptide. Functionally, it stimulates insulin release from the pancreas and leads to a reduction of hyperglycemia. In addition, Tirzepatide also increases the levels of adiponectin. Its dual agonism ability leads to a more significant reduction of hyperglycemia than GLP-1 agonist agents alone and lowers the user’s appetite.
Tirzepatide Benefits
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, which is FDA-approved for treating type 2 diabetes mellitus. It is important to note that tirzepatide is not approved for treating type-1 diabetes mellitus and has not been studied in patients with pancreatitis. Tirzepatide is a GIP receptor and GLP-1 receptor agonist, leading to significantly improved glycemic control in type 2 diabetics and significant weight reduction.
Tirzepatide Results
Patients with obesity and type 2 diabetes (T2D) or with overweight and T2D lost an estimated 34.4 pounds (15.7%) of body weight with 10 mg and 15 mg of tirzepatide (Mounjaro; Eli Lilly and Company), according to findings from the SURMOUNT-2 global phase 3 trial. Specifically, tirzepatide at 10 mg reduced body weight by 5% or more in 79.2% of patients and reduced average body weight by 12.8%, while the 15 mg dose reduced weight in 82.7% of patients and decreased average body weight by 14.7%.
Tirzepatide Used For Weight Loss
Tirzepatide is a once-weekly injection to decrease blood sugar. Since 2022 it has shown remarkable weight-loss effects and is on fast-track designation for its review for the treatment of obesity. On average, patients saw an astounding weight loss of over 20% of their initial body weight.
Tirzepatide and BPC 157 help with weight loss by decreasing food intake and slowing down how fast food travels through your digestive tract. This may help you feel fuller longer and reduce how much food you eat. Studies show this action may occur in the brain.
How it works:
●Reduce how much food is eaten.
●Stops the liver from making and releasing too much sugar.
●Slows down how quickly food leaves the stomach.
●The body releases insulin when blood sugar is high.
●The body removes excess sugar from the blood.
What is the difference between Tirzepatide and Semaglutide?
Tirzepatide acts on BOTH GIP and GLP-1 receptors, while Semaglutide acts only on GLP-1 receptors. Both drugs are effective weight-loss treatments. Tirzepatide is a dual-acting GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. Both are in the class of drugs known as incretin mimetics but have some differences.
Lifestyle modifications and calorie restriction will lead to overall better results. The benefits of weight loss are improved comorbidities of obesity such as diabetes, high blood pressure, abnormal blood lipids, and heart disease which can be seen with as little as a 5% weight loss.
Tirzepatide Side Effects
The most common side effects of Tirzepatide include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach (abdominal) pain. These are not all the possible side effects of Tirzepatide. Talk to your healthcare provider about any side effects you might experience.
Where to Buy Tirzepatide?
AASraw is the best place to buy Tirzepatide wholesale. All of our products come with an independent,third-party-issued Certificate of Analysis for identification, purity, and concentration. And we have bulk Tirzepatide for sale in stock!
AASraw is a Tirzepatide supplier and Tirzepatide manufacturer which has an independent lab and a large factory as support, all production will be carried out under CGMP regulation and a trackable quality control system. The tirzepatide supply system is stable, and both retail and wholesale orders are acceptable. If you want to buy Tirzepatide online, welcome to visit our website(aasraw.com).
Tirzepatide Testing Report-HNMR
What is HNMR and What does HNMR spectrum tell you? H Nuclear Magnetic Resonance (NMR) spectroscopy is an analytical chemistry technique used in quality control and research for determining the content and purity of a sample as well as its molecular structure. For example, NMR can quantitatively analyze mixtures containing known compounds. For unknown compounds, NMR can either be used to match against spectral libraries or to infer the basic structure directly. Once the basic structure is known, NMR can be used to determine molecular conformation in solution as well as studying physical properties at the molecular level such as conformational exchange, phase changes, solubility, and diffusion.
How to buy Tirzepatide from AASraw?
❶To contact us by our email inquiry system, or leave your WhatsApp number to us, our customer service representative(CSR) will contact you in 12 hours.
❷To provide us with your inquired quantity and address.
❸Our CSR will provide you with the quotation, payment term, tracking number, delivery ways, and estimated arrival date(ETA).
❹Payment done and the goods will be sent out in 12 hours.
❺Goods received and give comments.
Author of this article:
Dr. Monique Hong graduated from UK Imperial College London Faculty of Medicine
Scientific Journal paper Author:
1. Qi Liu
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, PR China
2. Sidar Copur
Department of Medicine, Koc University School of Medicine, Istanbul 34010, Turkey
3. Rouchan Ali
Department of Pharmaceutical Chemistry and Analysis, ISF College of Pharmacy, Moga 142001, Punjab, India
4. V. Thieu
Eli Lilly, Medical Affairs, Indianapolis, USA
In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Aasraw has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this substance.
References
[1] Lilly :Phase 3 Tirzepatide Results Show Superior A1C And Body Weight Reductions In Type 2 Diabetes”.Business Insider.RTTNews.19 October 2021.Archived from the original on 28 October 2021.Retrieved 28 October 2021.
[2] Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly’s SURPASS program” (Press release).Eli Lilly and Company.17 February 2021.Archived from the original on 28 October 2021.Retrieved 28 October 2021 – via PR Newswire.
[3] Kellaher,Colin (28 April 2022).”Eli Lilly’s Tirzepatide Meets Main Endpoints in Phase 3 Obesity Study”.MarketWatch.Dow Jones Newswires.Archived from the original on 29 April 2022.Retrieved 29 April 2022.
[4] Willard FS,Douros JD,Gabe MB,Showalter AD,Wainscott DB,Suter TM,et al.(September 2020).”Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist”.JCI Insight.5 (17).doi:10.1172/jci.insight.140532.PMC 7526454.PMID 32730231.
[5] Frederick MO,Boyse RA,Braden TM,Calvin JR,Campbell BM,Changi SM,et al.(2021).”Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing”.Organic Process Research & Development.25 (7):1628–1636.
[6] Frías JP,Davies MJ,Rosenstock J,Pérez Manghi FC,Fernández Landó L,Bergman BK,et al.(August 2021).”Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes”.The New England Journal of Medicine.385 (6):503–515.doi:10.1056/NEJMoa2107519.
Get a Bulk quotation
